Transcutaneous electrical nerve stimulation (TENS) for advanced cancer pain patients - A randomized, double-blind, placebo-controlled cross-over pilot study
- Conditions
- Cancer pain patients receiving palliative care
- Registration Number
- DRKS00007990
- Lead Sponsor
- Klinik für Palliativmedizin
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 26
Patients with cancer pain (caused by tumor or therapy; or associated with tumor) = 3 on an 11-point NRS the last 24 hours
- Age: = 18 years
- Patients receive at least 24 hours palliative care: on palliative care ward, palliative care consultant service or acute pain consultant service
- Verbal or cognitive inability to use TENS or to answer the questionnaire
- High probability of dying within the next week
- Pain that is not directly or indirectly related to tumor
Contraindications: Jones (2009) & Disselhoff (2012)
- electronic implants like pacemakers
- Metal implant on electrode site
- Arrhythmia
- Pregnancy
- Epilepsy
- Dermatological conditions or frail skin on electrode site
- Anamnestically known distinct allergy regarding electrodes
Drop-out criteria after inclusion:
- Patients that decide to stop TENS treatment (at any time or any reason).
- Further treatment is not indicated due a rapid deterioration of the patients’ clinical status according to the treating physician.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method - Change of mean pain intensity last 24 hours; Before and after the 24-hour-interventions and after the follow-up: at an average of one week; 11-point Numerical Rating Scale (NRS): 0-10; 0=no pain; 10=pain as bad as you can imagine
- Secondary Outcome Measures
Name Time Method